<DOC>
	<DOCNO>NCT00495378</DOCNO>
	<brief_summary>The purpose study determine alternate dose Epoetin alfa effective maintain hemoglobin level patient chemotherapy related anemia .</brief_summary>
	<brief_title>RAPID-2 . A Study Evaluate Effectiveness Alternate Dosing PROCRIT ( Epoetin Alfa ) Maintaining Hemoglobin Levels Patients With Chemotherapy Related Anemia</brief_title>
	<detailed_description>This retrospective chart review patient chemotherapy relate anemia . Two hundred ( 200 ) patient chemotherapy related anemia receive PROCRIT ( Epoetin alfa ) weekly schedule ( e.g. , every week frequently ) least 4 week , follow maintenance PROCRIT ( Epoetin alfa ) schedule le frequent dosing ( e.g . every 2 week , every 3 week , every 4 week ) least 6 week . Hemoglobin response maintenance initial treatment phase hemoglobin alternate dos PROCRIT ( Epoetin alfa ) evaluated.Study site record data Case Report Form would enter database . Data record , start PROCRIT ( Epoetin alfa ) initiation phase ( least 4 week duration ) , extend least 6 week maintenance therapy . A minimum 20 study site enrol data collection process.Data obtain analyzed reflect alternate dosing pattern PROCRIT ( Epoetin alfa ) therapy . The frequency percentage patient receive dose regimen summarize . Hemoglobin response maintenance initial treatment phase hemoglobin alternate dos PROCRIT ( Epoetin alfa ) evaluate . If PROCRIT ( Epoetin alfa ) discontinue , time reason ( ) discontinuation record . Patients receive PROCRIT ( Epoetin alfa ) subcutaneous injection weekly schedule ( e.g. , every week frequently ) least 4 week , follow maintenance PROCRIT ( Epoetin alfa ) schedule le frequent dosing ( e.g . every 2 week , 3 week , 4 week ) least 6 week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients chemotherapy related anemia Patients diagnosis malignancy Patients initial weekly PROCRIT ( Epoetin alfa ) therapy least 4 week Patients must receive PROCRIT ( Epoetin alfa ) maintenance therapy le frequent dosing ( e.g . every 2 week , every 3 week , every 4 week ) least 6 week immediately follow weekly dose . No previous diagnosis hemolytic anemia myelodysplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>PROCRIT</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>chemotherapy relate anemia</keyword>
</DOC>